Qingshu Meng
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Year:
2026
Year:
2025
EGFR amplification frequently happens within extrachromosome DNAs (ecDNAs) and is a major mutation in glioblastoma (GBM). However, targeting EGFR for GBM treatments has been unsuccessful. Here we characterized a long non-coding RNA (lncRNA) that is co-amplified with EGFR within ecDNAs that we name hidden EGFR long non-coding downstream RNA (HELDR). HELDR is a GBM-specific lncRNA that promotes tumorigenicity independent of EGFR signaling. HELDR globally binds genomic DNA and recruits the transcription co-activator p300 to the KAT7 promoter. p300-induced H3K27ac at the KAT7 promoter enlists other co-transcription factors, activating KAT7 transcription. KAT7 induces H3K14ac and H4K12ac that activate KAT7-driven gene programs that are critical for GBM malignancy. Targeting KAT7 or HELDR markedly enhances therapeutic effects of anti-EGFR treatments for GBM. These results not only reveal the role of HELDR in EGFR-driven GBM but also provide a strong rationale to characterize the role of lncRNAs co-amplified with driver oncogenes in human cancers.
Year:
2025
DNA repair dysregulation is a key driver of cancer development. Understanding the molecular mechanisms underlying DNA repair dysregulation in cancer cells is crucial for cancer development and therapies. Here, we report that enhancer of zeste homolog 2 (EZH2) directly methylates poly(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an essential enzyme involved in DNA repair, and regulates its activity. Functionally, EZH2-catalyzed methylation represses PARP1 catalytic activity, down-regulates the recruitment of x-ray repair cross-complementing group-1 to DNA lesions and its associated DNA damage repair; on the other hand, it protects the cells from nicotinamide adenine dinucleotide overconsumption upon DNA damage formation. Meanwhile, EZH2-mediated methylation regulates PARP1 transcriptional and oncogenic activity, at least in part, through impairing PARP1-E2F1 interaction and E2F1 transcription factor activity. EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity during DNA damage repair and cancer progression, which provides a rationale for combinational targeting EZH2 and PARP1 in cancer.
Year:
2024
Year:
2023
Year:
2023
Collaborators (13)
Rendong Yang
Associate Professor
Northwestern University Feinberg School of Medicine
Xiaoyu Zhang
Assistant Professor
Northwestern University
Xuesen Dong
Professor
The University of British Columbia
Shiyuan Cheng
Professor
Northwestern University Feinberg School of Medicine
Scott M Dehm
Faculty, Professor
University of Minnesota
Dongyu Zhao
Assistant Professor
Peking University
Song Xiao
Assistant Professor
Medical University of South Carolina
Luke Hoeppner
Faculty, Associate Professor
University of Minnesota
Douglas Yee
Professor
University of Minnesota
TINGYOU WANG
Research Assistant Professor
Northwestern University Feinberg School of Medicine
Sk. Kayum Alam
Researchers, Research Professional 5
University of Minnesota
Qi Cao
Associate Professor
Northwestern University
Longhou Fang
Associate Professor
Houston Methodist Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.